sofosbuvir and daclatasvir (n=30) vs. standard of care (n=30)
randomized controlled trial
some concerns about risk of bias
Sofosbuvir/Daclatasvir
Single daily oral tablet containing 400 mg sofosbuvir and 60mg daclatasvir with hydroxychloroquine 200mg twice daily, for 7 days, or until death/hospitalization.
Standard of care
Hydroxychloroquine.
Hydroxychloroquine in both groups. All patients received standard care according to the national Iranian treatment guidelines. All patients received azithromycin capsules (500mg for 6 days) with naproxen tablets (500mg, twice daily for 7 days), as well as40mg pantoprazole tablets.
COVID 19 outpatients
Patients excluded if oxygen saturation less than 93%.
Double-blind.
Single center, Miandrood Outpatient Medical Clinic in Surak, Mazandaran, Iran.
At Days 1, 3 and 5 patients were followed-up by phone call and at Day 7 by a personalvisit. At 30 days from enrolment, patients were followed-up by phone call to monitor fatigue, shortness of breath and anorexia.